Article Information
- Received December 14, 1998
- Revision received April 14, 1999
- Accepted April 23, 1999
- First published August 1, 1999.
- Version of record published August 1, 1999.
Author Information
- Kazutoshi Nishiyama1,
- Bruce D. Trapp1,
- Tsuneya Ikezu1,
- Richard M. Ransohoff1,
- Taisuke Tomita2,
- Takeshi Iwatsubo2,
- Ichiro Kanazawa3,
- Karen K. Hsiao4,
- Michael P. Lisanti5, and
- Takashi Okamoto1
- 1Department of Neurosciences, The Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio,
- 2Faculty of Pharmaceutical Sciences, Tokyo University, Tokyo, Japan,
- 3Division of Neuroscience, Graduate School of Medicine, Tokyo University, Tokyo, Japan,
- 4Department of Neurology, University of Minnesota, Minneapolis, Minnesota, and
- 5Department of Molecular Pharmacology and The Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, New York
Author contributions
Disclosures
- Received December 14, 1998.
- Revision received April 14, 1999.
- Accepted April 23, 1999.
This work was supported by United States Public Health Service Grant R29-MH56036, the Prentiss Foundation, and The John and Margaret Knupa Charitable Foundation (to T.O.). B.D.T. was supported by National Institutes of Health (NIH) Grants NS29818 and NS35058. T.I. was supported by NIH National Research Service Award Fellowship 1F32 AG0586-01. M.P.L. was supported by NIH National Cancer Institute Grant R01-CA-80250 and grants from the Charles E. Culpeper Foundation, the G. Harold and Leila Y. Mathers Charitable Foundation, and the Sidney Kimmel Foundation for Cancer Research. We greatly appreciate Ed Koo for providing presenilin antibodies and Sam Sisodia, Samuel Gandy, and Kazuaki Yoshikawa for providing APP antibodies.
Correspondence should be addressed to Dr. Takashi Okamoto, Department of Neurosciences, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195.
Online Impact